Tyra Biosciences has unveiled positive clinical proof-of-concept data for its investigational oral FGFR3-selective inhibitor, TYRA-300, in patients with metastatic urothelial (mUC) cancer. The data, presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, highlights the drug’s potential efficacy and safety profile in treating this aggressive form of bladder cancer.